



## Results of Annual General Meeting

29 November 2024

Opyl Limited (“OPL” or “the Company”) advises the results of the Annual General Meeting held today.

Voting on the resolutions put to the meeting was conducted via poll and the results of the poll are reflected in the attached annexure along with details of valid proxies received prior to the meeting.

All resolutions put to the meeting were approved by the required majority.

**This announcement has been authorised for release by the board**

**- ENDS -**

### **For investor enquiries:**

Bernice Averion  
Head of Marketing and Communications  
Phone: +61 415 311 957  
Email: [bernice.averion@opyl.ai](mailto:bernice.averion@opyl.ai)

### **About Opyl Limited (ASX: OPL)**

Opyl Limited is an AI company dedicated to leveraging data and technology to transform the landscape of clinical trials and medical research. With a commitment to innovation and strategic growth, Opyl is positioned to lead the way in shaping the future of healthcare solutions.

# Disclosure of Proxy Votes

## OPYL LIMITED

Annual General Meeting Friday,

29 November 2024

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

| Resolution  | Decided by Show of Hands (S) or Poll (P) | Total Number of Proxy Votes exercisable by proxies validly appointed | Proxy Votes          |                  |           |                    | Poll Results (if applicable) |                  |           | Results |
|---|--|--|----------------------|------------------|-----------|--------------------|------------------------------|------------------|-----------|---------|
|   |  |  | FOR                  | AGAINST          | ABSTAIN   | PROXY'S DISCRETION | FOR                          | AGAINST          | ABSTAIN   | OUTCOME |
| 1 ADOPTION OF REMUNERATION REPORT   | P  | 30,116,461   | 30,054,697<br>99.79% | 45,139<br>0.15%  | 70,488    | 16,625<br>0.06%    | 30,071,322<br>99.85%         | 45,139<br>0.15%  | 70,488    | Passed  |
| 2 ELECTION OF DIRECTOR – MR SAURABH JAIN  | P  | 55,502,924   | 55,441,008<br>99.89% | 45,291<br>0.08%  | 2,128,669 | 16,625<br>0.03%    | 55,457,633<br>99.92%         | 45,291<br>0.08%  | 2,128,669 | Passed  |
| 3 APPROVAL OF 10% PLACEMENT CAPACITY  | P  | 56,336,257   | 56,254,341<br>99.85% | 45,291<br>0.08%  | 1,295,336 | 36,625<br>0.06%    | 56,290,966<br>99.92%         | 45,291<br>0.08%  | 1,295,336 | Passed  |
| 4 APPROVAL OF ISSUE OF SECURITIES TO SAURABH JAIN                                       | P  | 54,150,767   | 53,998,515<br>99.72% | 115,627<br>0.21% | 3,480,826 | 36,625<br>0.07%    | 54,035,140<br>99.79%         | 115,627<br>0.21% | 3,480,826 | Passed  |
| 5 APPROVAL OF ISSUE OF SECURITIES TO DAMON RASHEED, DIRECTOR OF THE COMPANY             | P  | 53,420,231   | 53,267,979<br>99.72% | 115,627<br>0.22% | 2,788,869 | 36,625<br>0.07%    | 53,304,604<br>99.78%         | 115,627<br>0.22% | 2,788,869 | Passed  |
| 6 APPROVAL TO ISSUE 400,000 SHARES AND 200,000 OPTIONS                                  | P  | 56,406,593   | 56,295,824<br>99.80% | 74,144<br>0.13%  | 1,225,000 | 36,625<br>0.06%    | 56,332,449<br>99.87%         | 74,144<br>0.13%  | 1,225,000 | Passed  |
| 7 APPROVAL TO ISSUE 200,000 SHARES AND 100,000 OPTIONS                                  | P  | 56,406,593   | 56,295,824<br>99.80% | 74,144<br>0.13%  | 1,225,000 | 36,625<br>0.06%    | 56,332,449<br>99.87%         | 74,144<br>0.13%  | 1,225,000 | Passed  |
| 8 APPROVAL TO ISSUE SECURITIES TO IRWIN BIOTECH NOMINEES PTY LTD FOR CONVERSION OF LOAN | P  | 56,406,593   | 56,318,727<br>99.84% | 71,241<br>0.13%  | 1,225,000 | 16,625<br>0.03%    | 56,335,352<br>99.87%         | 71,241<br>0.13%  | 1,225,000 | Passed  |

For personal use only

